Breakthrough in Gynecologic Oncology
Experts have introduced an innovative algorithm that accurately identifies uterine cancer patients suitable for comprehensive genomic panel testing (CGP). This tool targets patients with uterine body cancer, which represents over 10% of cases, enabling precise application of advanced diagnostics.
Algorithm Design and Key Criteria
The algorithm employs a dual-metric approach to evaluate patients. First, it assesses gene variants using a tier system, prioritizing tiers 1 and 2 based on strong clinical evidence linking them to uterine cancer. Second, it measures variant allele frequency (VAF), the proportion of mutated DNA in tumor samples, setting a threshold above 40% to distinguish primary tumor mutations from secondary ones.
By integrating these metrics, researchers pinpointed mutations in 11 key genes associated with uterine cancers, including those linked to breast and colorectal origins, which often spread to the uterus.
Clinical Validation and Results
In a study of 702 uterine cancer patients receiving CGP, the algorithm flagged 19 cases (2.7%) as high-priority. All four patients confirmed via CGP to require such testing had uterine body cancer, achieving a positive predictive value (PPV) of 100%.
This precision stems from focusing on mutations exclusive to tumor cells, excluding those in non-tumor DNA where VAF remains low.
Expert Insights and Future Impact
Professor Kim Ki-dong emphasized the tool’s value: “This algorithm marks a realistic advance in distinguishing CGP-eligible patients from comprehensive genomic data, systematically selecting those most likely to benefit and enabling proactive management of high-risk uterine cancer cases.”
Prospective validation promises even broader accuracy, potentially expanding reliable early detection and improving clinical guidelines for uterine cancer screening.
The findings appear in the SCIE-listed journal Gynecologic Oncology (IF 4.1), underscoring its scientific rigor.
